vs

Side-by-side financial comparison of BayCom Corp (BCML) and InfuSystem Holdings, Inc (INFU). Click either name above to swap in a different company.

InfuSystem Holdings, Inc is the larger business by last-quarter revenue ($36.2M vs $25.9M, roughly 1.4× BayCom Corp). On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs 7.0%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $7.0M). Over the past eight quarters, InfuSystem Holdings, Inc's revenue compounded faster (6.4% CAGR vs 2.9%).

BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

BCML vs INFU — Head-to-Head

Bigger by revenue
INFU
INFU
1.4× larger
INFU
$36.2M
$25.9M
BCML
Growing faster (revenue YoY)
BCML
BCML
+2.4% gap
BCML
9.4%
7.0%
INFU
More free cash flow
BCML
BCML
$23.1M more FCF
BCML
$30.1M
$7.0M
INFU
Faster 2-yr revenue CAGR
INFU
INFU
Annualised
INFU
6.4%
2.9%
BCML

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCML
BCML
INFU
INFU
Revenue
$25.9M
$36.2M
Net Profit
$6.9M
Gross Margin
56.4%
Operating Margin
36.6%
10.3%
Net Margin
26.5%
Revenue YoY
9.4%
7.0%
Net Profit YoY
12.1%
EPS (diluted)
$0.63
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCML
BCML
INFU
INFU
Q4 25
$25.9M
$36.2M
Q3 25
$25.7M
$36.5M
Q2 25
$24.7M
$36.0M
Q1 25
$24.3M
$34.7M
Q4 24
$23.7M
$33.8M
Q3 24
$25.6M
$35.3M
Q2 24
$23.8M
$33.7M
Q1 24
$24.5M
$32.0M
Net Profit
BCML
BCML
INFU
INFU
Q4 25
$6.9M
Q3 25
$5.0M
$2.3M
Q2 25
$6.4M
$2.6M
Q1 25
$5.7M
$-267.0K
Q4 24
$6.1M
Q3 24
$6.0M
$1.8M
Q2 24
$5.6M
$717.0K
Q1 24
$5.9M
$-1.1M
Gross Margin
BCML
BCML
INFU
INFU
Q4 25
56.4%
Q3 25
57.1%
Q2 25
55.2%
Q1 25
55.2%
Q4 24
53.8%
Q3 24
53.9%
Q2 24
49.5%
Q1 24
51.5%
Operating Margin
BCML
BCML
INFU
INFU
Q4 25
36.6%
10.3%
Q3 25
26.3%
10.4%
Q2 25
35.3%
10.5%
Q1 25
31.6%
1.8%
Q4 24
34.2%
7.7%
Q3 24
32.4%
9.2%
Q2 24
31.9%
5.5%
Q1 24
33.3%
-2.6%
Net Margin
BCML
BCML
INFU
INFU
Q4 25
26.5%
Q3 25
19.5%
6.2%
Q2 25
25.8%
7.2%
Q1 25
23.4%
-0.8%
Q4 24
25.9%
Q3 24
23.5%
5.1%
Q2 24
23.6%
2.1%
Q1 24
24.0%
-3.5%
EPS (diluted)
BCML
BCML
INFU
INFU
Q4 25
$0.63
$0.09
Q3 25
$0.46
$0.11
Q2 25
$0.58
$0.12
Q1 25
$0.51
$-0.01
Q4 24
$0.55
$0.05
Q3 24
$0.54
$0.08
Q2 24
$0.50
$0.03
Q1 24
$0.51
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCML
BCML
INFU
INFU
Cash + ST InvestmentsLiquidity on hand
$3.2M
Total DebtLower is stronger
$19.6M
Stockholders' EquityBook value
$338.6M
$57.3M
Total Assets
$2.6B
$100.6M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCML
BCML
INFU
INFU
Q4 25
$3.2M
Q3 25
$955.0K
Q2 25
$720.0K
Q1 25
$1.5M
Q4 24
$527.0K
Q3 24
$380.0K
Q2 24
$146.0K
Q1 24
$822.0K
Total Debt
BCML
BCML
INFU
INFU
Q4 25
$19.6M
Q3 25
$20.9M
Q2 25
$26.3M
Q1 25
$28.7M
Q4 24
$23.9M
Q3 24
$28.0M
Q2 24
$34.2M
Q1 24
$29.9M
Stockholders' Equity
BCML
BCML
INFU
INFU
Q4 25
$338.6M
$57.3M
Q3 25
$334.3M
$55.5M
Q2 25
$330.6M
$54.5M
Q1 25
$329.3M
$55.1M
Q4 24
$324.4M
$57.5M
Q3 24
$321.7M
$55.5M
Q2 24
$315.3M
$53.5M
Q1 24
$314.2M
$52.3M
Total Assets
BCML
BCML
INFU
INFU
Q4 25
$2.6B
$100.6M
Q3 25
$2.6B
$98.9M
Q2 25
$2.6B
$100.8M
Q1 25
$2.6B
$104.3M
Q4 24
$2.7B
$103.6M
Q3 24
$2.6B
$105.3M
Q2 24
$2.6B
$108.5M
Q1 24
$2.6B
$104.8M
Debt / Equity
BCML
BCML
INFU
INFU
Q4 25
0.34×
Q3 25
0.38×
Q2 25
0.48×
Q1 25
0.52×
Q4 24
0.41×
Q3 24
0.50×
Q2 24
0.64×
Q1 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCML
BCML
INFU
INFU
Operating Cash FlowLast quarter
$31.8M
$7.1M
Free Cash FlowOCF − Capex
$30.1M
$7.0M
FCF MarginFCF / Revenue
116.2%
19.3%
Capex IntensityCapex / Revenue
6.7%
0.4%
Cash ConversionOCF / Net Profit
4.64×
TTM Free Cash FlowTrailing 4 quarters
$51.1M
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCML
BCML
INFU
INFU
Q4 25
$31.8M
$7.1M
Q3 25
$7.3M
$8.5M
Q2 25
$6.4M
$7.0M
Q1 25
$9.3M
$1.8M
Q4 24
$30.4M
$7.9M
Q3 24
$9.6M
$9.8M
Q2 24
$7.7M
$2.3M
Q1 24
$5.1M
$377.0K
Free Cash Flow
BCML
BCML
INFU
INFU
Q4 25
$30.1M
$7.0M
Q3 25
$6.2M
$8.4M
Q2 25
$5.6M
$6.8M
Q1 25
$9.1M
$1.6M
Q4 24
$28.7M
$7.4M
Q3 24
$9.4M
$9.8M
Q2 24
$7.4M
$2.0M
Q1 24
$3.9M
$195.0K
FCF Margin
BCML
BCML
INFU
INFU
Q4 25
116.2%
19.3%
Q3 25
24.3%
23.1%
Q2 25
22.8%
18.9%
Q1 25
37.6%
4.7%
Q4 24
121.1%
21.9%
Q3 24
36.6%
27.7%
Q2 24
31.2%
5.9%
Q1 24
16.1%
0.6%
Capex Intensity
BCML
BCML
INFU
INFU
Q4 25
6.7%
0.4%
Q3 25
4.3%
0.2%
Q2 25
3.0%
0.6%
Q1 25
0.6%
0.4%
Q4 24
7.2%
1.6%
Q3 24
1.0%
0.1%
Q2 24
1.0%
1.0%
Q1 24
4.7%
0.6%
Cash Conversion
BCML
BCML
INFU
INFU
Q4 25
4.64×
Q3 25
1.47×
3.76×
Q2 25
1.00×
2.70×
Q1 25
1.63×
Q4 24
4.96×
Q3 24
1.60×
5.45×
Q2 24
1.37×
3.22×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCML
BCML

Segment breakdown not available.

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

Related Comparisons